查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2135505

Valbenazine原料藥市場：全球市場預測，2026-2032年

Valbenazine API Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Valbenazine原料藥市場將成長至 1,282,970,000 美元，複合年成長率為 9.45%。

主要市場統計數據
基準年 2025 6.8153億美元
預計年份：2026年 7.4404億美元
預測年份 2032 1,282,970,000 美元
複合年成長率 (%) 9.45%

Valbenazine原料藥市場概覽

Valbenazine是一種活性藥物原料藥)，用於治療運動障礙，特別是與亨丁頓舞蹈症相關的遲發性運動障礙和舞蹈症。此原料藥市場受多種因素影響，包括滿足藥品品質要求、受控生產流程、監管、供應連續性以及最終製劑的穩定生產。因此，策略評估應重點關注每個目標產品的研發狀態、生產準備、品管系統、智慧財產權考量以及相關的監管途徑。

監管和生產方式的變革正在重塑Valbenazine原料藥的供應格局

當前情勢正朝著更緊密整合的流程發展，涵蓋原料藥開發、分析表徵、製程驗證和成品註冊申報。製造商和採購商比以往任何時候都更加重視雜質控制、嚴格的標準、完善的文件、隨時接受檢查以及可靠地採購專用中間體。其他優先事項包括安全的供應鏈、盡可能採用雙源採購計劃、環境控制以及生產柔軟性，以適應配方、劑量或地區註冊要求的變更。

人工智慧將為 API 開發和營運帶來哪些變化

人工智慧 (AI) 可透過加速文獻和專利檢索、識別製程開發變數、監控分析數據以及檢測生產作業中的潛在偏差，為Valbenazine原料藥的研發活動提供支援。機器學習工具還可以協助進行需求規劃、供應商風險篩檢、批次記錄審核和預測性維護計畫。這些應用需要檢驗的數據、人工監督、可解釋的決策標準，以及符合適用的電腦系統和藥品品質要求。人工智慧應作為合格的工藝、品質和法規專家的補充，而非替代。

全球Valbenazine原料藥市場的區域性洞察

在北美，既定的監管要求、專業的藥物研發能力以及對可靠原料藥文件的需求正在影響市場格局。在拉丁美洲，隨著藥品可及性的擴大，預計會出現一些機遇，但必須密切注意報名手續、進口限制和當地採購慣例。在歐洲，整個歐洲法規結構內嚴格的品質、環境和供應鏈要求至關重要。中東的特點是部分市場採用集中採購模式，並依賴受監管的國際供應商。非洲需要靈活的分銷和監管策略，以反映各國不同的能力。亞太地區擁有強大的藥品生產能力，但同時也面臨不同的核准體系、成本壓力以及對供應鏈韌性日益成長的關注。

東協、金磚國家、歐盟、七國集團、海灣合作理事會和北約市場的集團層級優先事項

東協市場需要各國協調一致地應對不同的註冊規則、進口要求和生產能力。金磚國家面臨巨大的藥品需求、監管成熟度參差不齊、國內生產政策和供應商選擇標準等諸多複雜因素的相互作用。歐盟尤其重視統一的品質標準、合格的監管和環境合規。七國集團市場通常要求提供詳細的技術文件、可追溯性和健全的檢驗體系。海灣合作理事會國家通常優先考慮可靠的進口供應、集中採購和國內註冊要求。雖然北約成員國沒有統一的藥品市場框架，但許多國家都將建立穩健的醫療保健供應鏈、確保合規性以及製定業務永續營運計劃作為優先事項。

Valbenazine原料藥策略中的國別考量

在澳洲和加拿大，必須與國家藥品監管機構保持一致並提交進口文件。在巴西和墨西哥，必須嚴格遵守當地的註冊、本地化和採購要求。中國和印度擁有龐大的藥品生產能力，以及完善的國內監管程序和不斷發展的品質標準。在日本和韓國，嚴格的產品品質、文件記錄以及與當地監管機構的協調至關重要。在法國、德國、義大利、西班牙和英國，必須嚴格遵守歐洲或國家藥品法規結構，特別注重品管系統和供應連續性。俄羅斯擁有獨特的監管和物流環境，需要進行國別評估。美國仍然是一個高度監管的國家，原料藥供應商必須提供有關品質、生產和法規的全面文件。

Valbenazine原料藥產業領導者的策略措施

產業領導企業應制定以風險為基礎的原料藥策略，涵蓋製程穩健性、雜質分析、分析方法驗證、供應商合格和變更管理。他們還應維護監管申報所需的完整技術文檔，定期進行品質審核，並評估關鍵原料和製造地的緊急時應對計畫。區域上市計劃應在做出商業性承諾前充分了解註冊要求。投資於數位化批次審核、供應鏈視覺性和嚴格控制的人工智慧工具可以提高應對力，但其實施應基於資料完整性、網路安全、驗證和課責。評估夥伴關係關係時，不僅應考慮價格，還應考慮其已證實的合規性和生產可靠性。

Valbenazine原料藥調查方法執行摘要

本概要採用結構化的定性框架，重點在於Valbenazine嗪原料藥的供應格局和法規環境特徵。評估內容包括治療相關性、生產和品質要求、監管差異、區域商業環境、集團層面的政策和採購、國家層面的市場進入考量、供應鏈韌性以及人工智慧的潛在作用。本概要不包含任何市場估算、預測、預估或針對特定公司的聲明。在做出任何投資或採購決策之前，應將檢驗。

結論：建構一個穩健、合規的Valbenazine原料藥平台。

在Valbenazine原料藥市場，化學、生產、品質、法規事務和供應鏈管理等各環節的嚴格執行至關重要。成功的關鍵在於原料藥品質的穩定性、詳實的文件、完善的區域合規計畫以及應對原料、物流和營運中斷的韌性。那些能夠將強大的技術控制、透明的供應商管治以及負責任的數位化技術應用相結合的企業，將更有能力支持在多元化的國際市場中可靠地開發和註冊成品。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章Valbenazine原料藥市場：依劑量強度分類

  • 40 Mg
  • 80 Mg

第8章：Valbenazine原料藥市場：依治療場景分類

  • 住院治療
  • 門診

第9章Valbenazine原料藥市場：依患者年齡層別分類

  • 18至64歲的成年人
    • 18-40歲
    • 41-64歲
  • 65歲及以上的老年人

第10章：Valbenazine原料藥市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 專科藥房

第11章Valbenazine原料藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章Valbenazine原料藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章Valbenazine原料藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Acharya Chemicals
  • Apotex Pharmachem
  • Crystal Pharmaceutical
  • FIS Fabbrica Italiana Sintetici
  • Farmhispania
  • Globe Quimica Ltda
  • Jubilant Generics
  • Lupin Manufacturing Solutions
  • Mitsubishi Tanabe Pharma
  • MSN Laboratories
  • MSN Life Sciences Private Ltd
  • Synthimed Labs
  • TAPI Technology & API Services
  • Teva Pharmaceutical Industries
  • Viatris

第16章 主要專家

Product Code: MRR-961F26FD648A

The Valbenazine API Market is projected to grow by USD 1,282.97 million at a CAGR of 9.45% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 681.53 million
Estimated Year [2026] USD 744.04 million
Forecast Year [2032] USD 1,282.97 million
CAGR (%) 9.45%

Valbenazine API Market: Executive Overview

Valbenazine is an active pharmaceutical ingredient used in medicines targeting movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease. The API landscape is shaped by pharmaceutical quality requirements, controlled manufacturing processes, regulatory oversight, supply continuity, and the need to support consistent finished-dose production. Strategic assessment should therefore focus on development status, manufacturing readiness, quality systems, intellectual-property considerations, and the regulatory pathways relevant to each intended product.

Regulatory and Manufacturing Shifts Reshaping Valbenazine API Supply

The landscape is moving toward tighter integration between API development, analytical characterization, process validation, and finished-product regulatory submissions. Manufacturers and buyers are placing greater emphasis on impurity control, robust specifications, documentation packages, inspection readiness, and reliable sourcing of specialized intermediates. Additional priorities include secure supply chains, dual-source planning where feasible, environmental controls, and manufacturing flexibility that can support changes in formulation, dosage strength, or regional registration requirements.

How Artificial Intelligence Is Changing API Development and Operations

Artificial intelligence can support valbenazine API activities by accelerating literature and patent review, identifying process-development variables, monitoring analytical data, and detecting potential deviations in manufacturing operations. Machine-learning tools may also assist demand planning, supplier-risk screening, batch-record review, and preventive-maintenance programs. These applications require validated data, human oversight, explainable decision criteria, and compliance with applicable computerized-system and pharmaceutical quality expectations; AI should augment rather than replace qualified process, quality, and regulatory experts.

Regional Insights Across the Global Valbenazine API Landscape

North America is influenced by established regulatory expectations, specialty-pharmaceutical development capabilities, and demand for dependable API documentation. Latin America presents opportunities linked to expanding pharmaceutical access while requiring careful attention to registration procedures, import controls, and local procurement practices. Europe emphasizes stringent quality, environmental, and supply-chain requirements across the European regulatory framework. The Middle East is shaped by centralized procurement in some markets and reliance on compliant international suppliers. Africa requires adaptable distribution and regulatory strategies that reflect varied national capacities. Asia-Pacific combines strong pharmaceutical manufacturing capabilities with diverse approval systems, cost pressures, and growing interest in supply-chain resilience.

Group-Level Priorities Across ASEAN, BRICS, EU, G7, GCC, and NATO Markets

ASEAN markets require coordinated attention to differing national registration rules, import requirements, and manufacturing capabilities. BRICS economies combine substantial pharmaceutical demand with varied regulatory maturity, domestic-production policies, and sourcing preferences. The European Union places particular weight on harmonized quality expectations, qualified-person oversight, and environmental compliance. G7 markets generally demand extensive technical documentation, traceability, and inspection readiness. GCC countries often emphasize reliable imported supply, centralized purchasing, and national registration requirements. NATO members are not governed by a single pharmaceutical market framework, but many prioritize resilient medical supply chains, regulatory compliance, and continuity planning.

Country-Level Considerations for Valbenazine API Strategy

Australia and Canada require alignment with national therapeutic-goods authorities and import documentation. Brazil and Mexico call for careful navigation of local registration, localization, and procurement requirements. China and India combine significant pharmaceutical manufacturing capacity with detailed domestic regulatory procedures and evolving quality expectations. Japan and South Korea emphasize rigorous product quality, documentation, and local regulatory engagement. France, Germany, Italy, Spain, and the United Kingdom require strong compliance with European or national pharmaceutical frameworks, with particular attention to quality systems and supply continuity. Russia presents a distinct regulatory and logistics environment requiring country-specific assessment. The United States remains a highly regulated setting in which API suppliers must support comprehensive quality, manufacturing, and regulatory documentation.

Strategic Actions for Valbenazine API Industry Leaders

Industry leaders should establish a risk-based API strategy covering process robustness, impurity profiles, analytical-method validation, supplier qualification, and change control. They should maintain complete technical documentation for regulatory submissions, conduct routine quality audits, and evaluate contingency plans for critical raw materials and manufacturing sites. Regional launch planning should map registration requirements before commercial commitments are made. Investment in digital batch review, supply-chain visibility, and carefully governed AI tools can improve responsiveness, but implementation should remain anchored in data integrity, cybersecurity, validation, and accountability. Partnerships should be assessed on demonstrated compliance and manufacturing reliability rather than price alone.

Research Methodology for the Valbenazine API Executive Summary

This summary uses a structured qualitative framework focused on the characteristics of the valbenazine API supply and regulatory environment. The assessment considers therapeutic relevance, manufacturing and quality requirements, regulatory variation, regional operating conditions, group-level policy and procurement context, country-level market access considerations, supply-chain resilience, and the potential role of artificial intelligence. No market estimates, market shares, forecasts, or company-specific claims are used. Conclusions should be validated against current regulatory filings, official guidance, inspection records, scientific literature, patent information, and directly verified supplier documentation before investment or sourcing decisions.

Conclusion: Building a Compliant and Resilient Valbenazine API Platform

The valbenazine API landscape rewards disciplined execution across chemistry, manufacturing, quality, regulatory affairs, and supply-chain management. Success depends on consistent API quality, defensible documentation, region-specific compliance planning, and resilience against raw-material, logistics, and operational disruptions. Organizations that combine robust technical controls with transparent supplier governance and responsible digital adoption will be better positioned to support reliable finished-product development and registration across diverse international markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Valbenazine API Market, by Dosage Strength

  • 7.1. Introduction
  • 7.2. 40 Mg
  • 7.3. 80 Mg

8. Valbenazine API Market, by Treatment Setting

  • 8.1. Introduction
  • 8.2. Inpatient
  • 8.3. Outpatient

9. Valbenazine API Market, by Patient Age Group

  • 9.1. Introduction
  • 9.2. Adults 18 To 64
    • 9.2.1. 18 To 40
    • 9.2.2. 41 To 64
  • 9.3. Elderly 65 Plus

10. Valbenazine API Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Retail Pharmacy
  • 10.4. Specialty Pharmacy

11. Valbenazine API Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. Valbenazine API Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. Valbenazine API Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Acharya Chemicals
  • 15.2. Apotex Pharmachem
  • 15.3. Crystal Pharmaceutical
  • 15.4. F.I.S. Fabbrica Italiana Sintetici
  • 15.5. Farmhispania
  • 15.6. Globe Quimica Ltda
  • 15.7. Jubilant Generics
  • 15.8. Lupin Manufacturing Solutions
  • 15.9. Mitsubishi Tanabe Pharma
  • 15.10. MSN Laboratories
  • 15.11. MSN Life Sciences Private Ltd
  • 15.12. Synthimed Labs
  • 15.13. TAPI Technology & API Services
  • 15.14. Teva Pharmaceutical Industries
  • 15.15. Viatris

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Valbenazine API Market, Years Considered for the Study
  • FIGURE 2. Global Valbenazine API Market, Research Design
  • FIGURE 3. Global Valbenazine API Market, Research Framework
  • FIGURE 4. Global Valbenazine API Market, Data Triangulation
  • FIGURE 5. Global Valbenazine API Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Valbenazine API Market Size, by Dosage Strength, 2025 vs 2032 (%)
  • FIGURE 7. Global Valbenazine API Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Valbenazine API Market Size, by Treatment Setting, 2025 vs 2032 (%)
  • FIGURE 9. Global Valbenazine API Market Size, by Treatment Setting, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Valbenazine API Market Size, by Patient Age Group, 2025 vs 2032 (%)
  • FIGURE 11. Global Valbenazine API Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Valbenazine API Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global Valbenazine API Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Valbenazine API Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Valbenazine API Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Valbenazine API Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Valbenazine API Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Valbenazine API Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Valbenazine API Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Valbenazine API Market Segmentation & Coverage
  • TABLE 2. Global Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 4. Global 40 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global 40 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global 40 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global 80 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global 80 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global 80 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 11. Global Inpatient Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 12. Global Inpatient Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 13. Global Inpatient Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 14. Global Outpatient Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Outpatient Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Outpatient Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 18. Global Adults 18 To 64 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 19. Global Adults 18 To 64 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 20. Global Adults 18 To 64 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 21. Global 18 To 40 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global 18 To 40 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global 18 To 40 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global 41 To 64 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global 41 To 64 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global 41 To 64 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Elderly 65 Plus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Elderly 65 Plus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Elderly 65 Plus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 31. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Asia-Pacific Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Asia-Pacific Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 43. Asia-Pacific Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 44. Asia-Pacific Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 45. Asia-Pacific Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 46. Asia-Pacific Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 47. North America Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. North America Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 49. North America Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 50. North America Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 51. North America Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 52. North America Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 53. Latin America Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Latin America Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 55. Latin America Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 56. Latin America Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 57. Latin America Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 58. Latin America Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 59. Europe Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Europe Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 61. Europe Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 62. Europe Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 63. Europe Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 64. Europe Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 65. Middle East Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Middle East Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 67. Middle East Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 68. Middle East Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 69. Middle East Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 70. Middle East Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 71. Africa Valbenazine API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Africa Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 73. Africa Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 74. Africa Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 75. Africa Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 76. Africa Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 77. Global Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. ASEAN Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. ASEAN Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 80. ASEAN Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 81. ASEAN Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 82. ASEAN Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 83. ASEAN Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 84. GCC Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. GCC Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 86. GCC Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 87. GCC Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 88. GCC Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 89. GCC Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 90. European Union Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. European Union Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 92. European Union Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 93. European Union Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 94. European Union Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 95. European Union Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 96. BRICS Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. BRICS Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 98. BRICS Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 99. BRICS Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 100. BRICS Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 101. BRICS Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 102. G7 Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. G7 Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 104. G7 Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 105. G7 Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 106. G7 Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 107. G7 Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 108. NATO Valbenazine API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. NATO Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 110. NATO Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 111. NATO Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 112. NATO Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 113. NATO Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 114. Global Valbenazine API Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 115. United States Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 116. United States Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 117. United States Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 118. United States Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 119. United States Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 120. United States Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 121. Canada Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 122. Canada Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 123. Canada Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 124. Canada Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 125. Canada Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 126. Canada Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 127. Mexico Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 128. Mexico Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 129. Mexico Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 130. Mexico Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 131. Mexico Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 132. Mexico Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 133. Brazil Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 134. Brazil Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 135. Brazil Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 136. Brazil Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 137. Brazil Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 138. Brazil Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 139. United Kingdom Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 140. United Kingdom Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 141. United Kingdom Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 142. United Kingdom Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 143. United Kingdom Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 144. United Kingdom Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 145. Germany Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 146. Germany Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 147. Germany Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 148. Germany Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 149. Germany Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 150. Germany Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 151. France Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 152. France Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 153. France Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 154. France Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 155. France Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 156. France Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 157. Russia Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 158. Russia Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 159. Russia Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 160. Russia Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 161. Russia Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 162. Russia Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 163. Italy Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 164. Italy Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 165. Italy Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 166. Italy Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 167. Italy Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 168. Italy Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 169. Spain Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 170. Spain Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 171. Spain Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 172. Spain Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 173. Spain Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 174. Spain Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 175. China Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 176. China Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 177. China Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 178. China Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 179. China Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 180. China Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 181. India Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 182. India Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 183. India Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 184. India Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 185. India Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 186. India Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 187. Japan Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 188. Japan Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 189. Japan Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 190. Japan Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 191. Japan Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 192. Japan Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 193. Australia Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 194. Australia Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 195. Australia Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 196. Australia Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 197. Australia Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 198. Australia Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 199. South Korea Valbenazine API Market Size, 2017-2032 (USD Million)
  • TABLE 200. South Korea Valbenazine API Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 201. South Korea Valbenazine API Market Size, by Treatment Setting, 2017-2032 (USD Million)
  • TABLE 202. South Korea Valbenazine API Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 203. South Korea Valbenazine API Market Size, by Adults 18 To 64, 2017-2032 (USD Million)
  • TABLE 204. South Korea Valbenazine API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 205. Global Valbenazine API Market Share, by Key Player, 2025
  • TABLE 206. Global Valbenazine API Market, Key Experts